Reduced Ejection News Today

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

The trial missed its primary endpoint, but makes unique contributions; many see it as further evidence that the treatment helps iron-deficient patients with heart failure.

The American Heart Association (AHA) Scientific Sessions 2022 in Chicago, and virtually, is set for November 5-7 at McCormick Place. Highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions and featured science sessions.

Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.

Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE...

Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection FractionSANTA CLARA, Calif.--(BUSINESS WIRE)--#accucinch--Ancora Heart, Inc., a company developing a novel device-based therapy to address heart...

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American... | February 15, 2022

But DREAM-HF trial saw no reduction in hospitalizations for heart failure events among adults with heart failure who received a stem cell treatment

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehab programs.